EN DE
Watch iNtRON Biotechnology Inc for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

iNtRON Biotechnology Inc (048530) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of iNtRON Biotechnology Inc stock KRW 2,028, price KRW 2,475, that is 18.1% below the price, quality 44 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7048530000

IB iNtRON Biotechnology Inc logo Thin data Nov 16, 2026

iNtRON Biotechnology Inc

048530 · KQ

Expensive (fair value 18% below the price), weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Ranks above peers (8/11) 
Quality 44/100 
Mixed Growth (revenue YoY −10.6 %/yr in KRW) 
4.0% dividend yield · Watch coverage
Fair value 2,028 KRW · Overvalued 
Falling price (downtrend) 
Loss-making · -156.1% net margin (TTM) 
Negative free cash flow 
Narrow moat 10/100 · thin data
Thin data 
Estimate
Watch iNtRON Biotechnology Inc for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

25,264 KRW 2,330 KRW Fair Value 2,028 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 2,330 KRW – 25,264 KRW · fair‑value band 1,521 KRW – 2,535 KRW · the 2,475 KRW price screens above the 2,028 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 16, 2026.

Follow iNtRON Biotechnology in your weekly email

Every Wednesday you see whether iNtRON Biotechnology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

iNtRON Biotechnology, Inc. engages in the development of novel biopharmaceutical drugs in South Korea. It develops bacteriophage and endolysin based drugs through itLysin and IMPA platform. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.

Stock analysis

iNtRON Biotechnology Inc (048530) currently trades at 2,475 KRW, while our estimate is 2,028 KRW, 18% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1,521 KRW (bear) to 2,535 KRW (bull), the price of 2,475 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2023: revenue and profit before it include the divested business. Growth is measured afresh from 2023.

iNtRON Biotechnology Inc reported revenue of 5.7B KRW in FY2025 versus 29.3B KRW in FY2021, a compound −33.5%/yr. Reported net income was −9.0B KRW in FY2025.

Key figures

Market cap 76.0B KRW (≈ $57.0M) Micro · P/S ratio 16.3 · EPS (TTM) −290.00 KRW · Dividend yield 4.0% · Return on equity −11.7% · Return on assets (EBIT) −4.1% (5-year average) · Operating margin −120% · Revenue (TTM) 5.7B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 63% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −18%, 048530 screens richer than that median.

Fair Value

Bear 1,521 KRW Fair Value 2,028 KRW Bull 2,535 KRW
Price 2,475 KRW · Downside -18.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 44/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 12
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 99
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 23
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2023: revenue and profit before it include the divested business. Growth is measured afresh from 2023.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
34.9% (2020) → −137.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

048530 screens overvalued: fair value 18% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare iNtRON Biotechnology Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 7/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 44 · Above median
Fair Value upside −18.1% · Above median
Profitability
Return on assets −12.1% · Above median
Net margin (12 months) −156.1% · Bottom 25%
Operating margin (12 months) −119.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 12.0% · Above median
Dividend yield (12 months) 4.0% · Top 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.09× · Cheapest 25%
P/S (12 months) 13.23× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)9 · sector 2
FUTURE (revenue growth)60 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)81 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $957.76 $1,275 +33% vs 048530
Vertex Pharmaceuticals Incorporated VRTX $534.20 $592.46 +11% vs 048530
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs 048530
argenx SE ARGX $947.52 $908.40 −4% vs 048530
CSL Limited CSL A$199.38 A$186.49 −6% vs 048530
Moderna, Inc MRNA $206.80 $135.64 −34% vs 048530
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs 048530
Revolution Medicines, Inc RVMD $162.69 $88.78 −45% vs 048530
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs 048530
Royalty Pharma plc RPRX $68.68 $19.01 −72% vs 048530

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

iNtRON Biotechnology Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "iNtRON Biotechnology Inc Fair Value". https://www.fairvalue-calculator.com/stock/048530

Frequently asked questions

Is iNtRON Biotechnology Inc (048530) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 2,028 KRW versus a price of 2,475 KRW, about 18% lower (overvalued).
What is the fair value of 048530?
Our estimate for iNtRON Biotechnology Inc is 2,028 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 2,475 KRW.
What is the quality score of 048530?
iNtRON Biotechnology Inc has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for iNtRON Biotechnology Inc (048530)?
Our calculated price target is the estimate of 2,028 KRW (as of Nov 16, 2026). Cautious scenario 1,521 KRW, optimistic scenario 2,535 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the iNtRON Biotechnology Inc stock forecast for 2026?
Our estimate puts fair value at 2,028 KRW, about 18% lower versus a price of 2,475 KRW (overvalued). Cautious scenario 1,521 KRW, optimistic scenario 2,535 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of iNtRON Biotechnology Inc (048530)?
iNtRON Biotechnology Inc reported trailing-twelve-month revenue of about 5.7B KRW (latest available figure, as of Nov 16, 2026).
Does iNtRON Biotechnology Inc pay a dividend?
iNtRON Biotechnology Inc currently shows a dividend yield of 4.04% relative to its recent price (as of Nov 16, 2026).
How much is the dividend of iNtRON Biotechnology Inc (048530)?
iNtRON Biotechnology Inc pays a dividend of 100.00 KRW per share a year, a dividend yield of 4.0%. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of iNtRON Biotechnology Inc (048530)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For iNtRON Biotechnology Inc it is 2,028 KRW per share (as of Nov 16, 2026), against a price of 2,475 KRW.
Is iNtRON Biotechnology Inc stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 048530 trades above its calculated fair value: price 2,475 KRW, fair value 2,028 KRW, a gap of about −18% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 048530?
No. The price is what the market pays today (2,475 KRW); the fair value is what the company's own numbers justify (2,028 KRW). For iNtRON Biotechnology Inc the two are 447.39 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is iNtRON Biotechnology Inc worth?
The market values iNtRON Biotechnology Inc at about 76.0B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 2,475 KRW; our models calculate a fair value of 2,028 KRW per share.
What do the bullish and bearish scenarios say about 048530?
Our models span a range for iNtRON Biotechnology Inc: cautious scenario 1,521 KRW, base 2,028 KRW, optimistic 2,535 KRW per share (as of Nov 16, 2026, price 2,475 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of iNtRON Biotechnology Inc (048530)?
Balance-sheet figures for iNtRON Biotechnology Inc (as of Nov 16, 2026): return on equity −11.7%, debt of 0.01 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 048530 from its 52-week high?
iNtRON Biotechnology Inc trades at 2,475 KRW, about 63% below its 52-week high of 6,650 KRW and 6% above the low of 2,330 KRW (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of 2,028 KRW is for.
Which stocks are comparable to iNtRON Biotechnology Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is iNtRON Biotechnology Inc stock attractive at the current price?
The data as of Nov 16, 2026: price 2,475 KRW, calculated fair value 2,028 KRW (−18%), Quality Score 44/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3% above its aggregate fair value. iNtRON Biotechnology Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of iNtRON Biotechnology Inc (048530)?
The closing price on Nov 17, 2026 was 2,475 KRW. Our estimate is 2,028 KRW, about 18% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with iNtRON Biotechnology Inc right now?
Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of iNtRON Biotechnology Inc

How large is the market capitalisation of iNtRON Biotechnology Inc (048530)?
The market capitalisation of iNtRON Biotechnology Inc is 76.0B KRW (≈ $57.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of iNtRON Biotechnology Inc (048530)?
The price-to-sales ratio of iNtRON Biotechnology Inc is 16.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of iNtRON Biotechnology Inc (048530)?
Earnings per share at iNtRON Biotechnology Inc are −290.00 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of iNtRON Biotechnology Inc (048530)?
The dividend yield of iNtRON Biotechnology Inc is 4.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the return on equity of iNtRON Biotechnology Inc (048530)?
The return on equity (ROE) of iNtRON Biotechnology Inc is −11.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of iNtRON Biotechnology Inc (048530)?
On an EBIT basis the return on assets of iNtRON Biotechnology Inc is −4.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of iNtRON Biotechnology Inc (048530)?
The operating margin of iNtRON Biotechnology Inc is −120% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at iNtRON Biotechnology Inc (048530)?
Revenue at iNtRON Biotechnology Inc is growing 12.0% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at iNtRON Biotechnology Inc (048530)?
Earnings per share at iNtRON Biotechnology Inc are growing 25.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does iNtRON Biotechnology Inc (048530) generate?
The free cash flow of iNtRON Biotechnology Inc is −7.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch iNtRON Biotechnology Inc in the live analysis

One click puts iNtRON Biotechnology Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.